Samil Pharmaceutical Co.,Ltd (KRX: 000520)

Samil Pharmaceutical Co.,Ltd Statistics

Total Valuation

Samil Pharmaceutical Co.,Ltd has a market cap or net worth of KRW 272.59 billion. The enterprise value is 413.92 billion.

Market Cap	272.59B
Enterprise Value	413.92B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Samil Pharmaceutical Co.,Ltd has 21.23 million shares outstanding. The number of shares has decreased by -7.68% in one year.

Current Share Class	n/a
Shares Outstanding	21.23M
Shares Change (YoY)	-7.68%
Shares Change (QoQ)	-4.98%
Owned by Insiders (%)	23.34%
Owned by Institutions (%)	5.37%
Float	15.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.01
PB Ratio	1.55
P/TBV Ratio	1.58
P/FCF Ratio	134.01
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.30, with an EV/FCF ratio of 203.49.

EV / Earnings	-352.49
EV / Sales	1.95
EV / EBITDA	39.30
EV / EBIT	81.35
EV / FCF	203.49

Financial Position

The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.83.

Current Ratio	0.75
Quick Ratio	0.34
Debt / Equity	0.83
Debt / EBITDA	13.80
Debt / FCF	71.44
Interest Coverage	3.93

Financial Efficiency

Return on equity (ROE) is -0.76% and return on invested capital (ROIC) is 1.00%.

Return on Equity (ROE)	-0.76%
Return on Assets (ROA)	0.83%
Return on Capital (ROIC)	1.00%
Revenue Per Employee	363.12M
Profits Per Employee	-2.01M
Employee Count	585
Asset Turnover	0.55
Inventory Turnover	3.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +104.93% in the last 52 weeks. The beta is 0.34, so Samil Pharmaceutical Co.,Ltd's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	+104.93%
50-Day Moving Average	14,140.40
200-Day Moving Average	11,074.95
Relative Strength Index (RSI)	49.44
Average Volume (20 Days)	661,216

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Samil Pharmaceutical Co.,Ltd had revenue of KRW 212.42 billion and -1.17 billion in losses. Loss per share was -71.15.

Revenue	212.42B
Gross Profit	80.36B
Operating Income	5.09B
Pretax Income	3.00B
Net Income	-1.17B
EBITDA	10.53B
EBIT	5.09B
Loss Per Share	-71.15

Balance Sheet

The company has 4.00 billion in cash and 145.32 billion in debt, giving a net cash position of -141.33 billion or -6,657.09 per share.

Cash & Cash Equivalents	4.00B
Total Debt	145.32B
Net Cash	-141.33B
Net Cash Per Share	-6,657.09
Equity (Book Value)	174.65B
Book Value Per Share	8,263.35
Working Capital	-28.62B

Cash Flow

In the last 12 months, operating cash flow was 23.07 billion and capital expenditures -21.03 billion, giving a free cash flow of 2.03 billion.

Operating Cash Flow	23.07B
Capital Expenditures	-21.03B
Free Cash Flow	2.03B
FCF Per Share	95.82

Margins

Gross margin is 37.83%, with operating and profit margins of 2.39% and -0.55%.

Gross Margin	37.83%
Operating Margin	2.39%
Pretax Margin	1.41%
Profit Margin	-0.55%
EBITDA Margin	4.96%
EBIT Margin	2.39%
FCF Margin	0.96%

Dividends & Yields

Samil Pharmaceutical Co.,Ltd does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	7.68%
Shareholder Yield	7.68%
Earnings Yield	-0.55%
FCF Yield	0.75%

Stock Splits

The last stock split was on March 24, 2023. It was a forward split with a ratio of 1.1.

Last Split Date	Mar 24, 2023
Split Type	Forward
Split Ratio	1.1

Scores

Samil Pharmaceutical Co.,Ltd has an Altman Z-Score of 1.06. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.06
Piotroski F-Score	n/a